Pharm2Farm reported on Thursday the availability of the Pro-Larva mask that integrates the unique British technology based on copper nanoparticles to create an effective virucidal barrier against Covid-19 and other types of viruses, including the flu virus.
The company added that the Pro-Larva mask is the new antiviral mask that kills 99.9% of Covid-19 in the first five minutes of contact. The new revolutionary device, unlike the traditional masks, offers an unsurpassed level of protection against viruses, not only for those around the wearer but also for the wearer.
According to the company, the Pro-Larva mask is designed for hospitals, retirement homes, schools, retail and leisure sectors.
A spin out from Nottingham Trent University, Pharm2Farm Ltd produces and sells these masks through an exclusive license from NTU.
Oxurion in talks to acquire Eclevar's MedTech CRO business and assets
FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test
Insmed's ARIKAYCE sNDA granted priority review by FDA
ProBio and Kun Tuo collaborate to deliver integrated CDMO-CRO solutions for advanced therapies
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
Aptar and Aceso Therapeutics partner to advance inhaled cystic fibrosis therapy
Immuron signs US distribution deal for PROIBS
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
Pulnovo Medical commences enrolment in PULSE-LHD IDE clinical trial
Implantica's RefluxStop receives US FDA approval
Sectra to provide Education Portal to Loyalist College for medical imaging training
Aqua Medical treats second type 2 diabetes patient in IDE trial of investigational PIMA procedure
Abbott and NACHC launch nationwide Food for Health initiative
Galmed reports positive preclinical results for Aramchol in prostate cancer